Mode
Text Size
Log in / Sign up
N/A N=105 Treatment

Study of the Use of Low Level Laser Light Therapy to Treat Toenail Fungus

Onychomycosis

Enrolled (actual)
105
Serious AEs
0.0%
Results posted
Dec 2015
Primary outcome: Primary: Proportion of Toenails Attaining 25 Percent (%) or More Increase in Clear Nail — 65 percentage of toenails

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Erchonia FX-405™ Laser (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Erchonia Corporation
Primary completion
Apr 2012

Outcome Measures

OutcomeResultp-value
PRIMARY
Proportion of Toenails Attaining 25 Percent (%) or More Increase in Clear Nail
65
SECONDARY
Change in Millimeter (mm) of Clear Nail Bed
4.99 <0.0001 sig
SECONDARY
Change in Percent (%) of mm Clear Nail
30.36 <0.0001 sig

Summary

The purpose of this study is to determine whether low level laser light is effective in the treatment of toenail fungus.

Eligibility Criteria

Inclusion Criteria

  • Onychomycosis present in at least one great toenail.
  • Disease involvement is at least 25%.
  • Subject is willing and able to refrain from employing other (non-study) treatments (traditional or alternative) for his or her toenail onychomycosis throughout study participation.
  • Subject is willing and able to refrain from the use of nail cosmetics such as clear and/or colored nail lacquers throughout study participation.

Exclusion Criteria

  • Spikes of disease extending to nail matrix.
  • Infection involving lunula, e.g., genetic nail disorders, primentary disorders.
  • Less than 2mm clear (unaffected) nail plate length beyond the proximal fold.
  • Presence of dermatophytoma (thick masses of fungal hyphae and necrotic keratin between the nail plate and nail bed).
  • Chronic plantar (moccasin) tinea pedis.
  • History of current or past psoriasis of the skin and/or nails.
  • Concurrent lichen planus.
  • Onychogryphosis.
  • Any of the following conditions of the great toenail:
  • proximal subungual onychomycosis
  • white superficial onychomycosis
  • dermatophytoma or "yellow spike/streak"
  • exclusively lateral disease
  • confounding problems/abnormalities of the great toenail(s).
  • Any abnormality that could prevent a normal appearing nail if clearing of infection is achieved.
  • Inability for the toenail to become normal in the opinion of the investigator.
  • History of multiple repeated failures with previous therapies for onychomycosis.
  • Trauma to the affected great toenail(s).
  • Use of oral antifungal agents in the past 6 months.
  • Use of topical antifungal agents in the past 1 month.
  • Prior surgical treatment of the affected great toe(s).
  • Cancer and/or treatment of any type of cancer within the last six months.
  • Peripheral vascular disease or peripheral circulatory impairment.
  • History of uncontrolled diabetes mellitus.
  • Known immunodeficiency.
  • Known sensitivity, or contraindication, to light therapy.
  • Pregnant, breast feeding, or planning pregnancy prior to the end of study participation.
  • Serious mental health illness such as dementia or schizophrenia; psychiatric hospitalization in the past two years.
  • Developmental disability or cognitive impairment that would preclude adequate comprehension of the informed consent form and/or ability to follow study subject requirements and/or record the necessary study measurements.
  • Involvement in litigation and/or receiving disability benefits related in any way to the parameters of the study.
  • Participation in a clinical study or other type of research in the past 30 days.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01534689). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search